Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Open Label, Multicenter, Partially Randomized, Safety Study of One Cycle of Promethera HepaStem in Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Paediatric Patients.

Next Previous
Trial Profile

A Prospective, Open Label, Multicenter, Partially Randomized, Safety Study of One Cycle of Promethera HepaStem in Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Paediatric Patients.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Crigler-Najjar syndrome; Inborn urea cycle disorders
  • Focus Adverse reactions; First in man
  • Acronyms HEP 001; UKHEP001
  • Sponsors Cellaion; Promethera Biosciences

Most Recent Events

  • 18 Feb 2019 Results evaluating safety and preliminary efficacy of HepaStem in Urea Cycle Disorders and Crigler-Najjar Syndrome Patients published in the Transplantation
  • 18 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 17 Feb 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top